|Videos|February 27, 2017

Medicare Part D and Oncology

Marc O'Connor, COO and chief strategy officer at Curant Health, discusses how the shift to Medicare Part D could impact patients undergoing treatment for cancer.

Marc O'Connor, COO and chief strategy officer at Curant Health, discusses how the shift to Medicare Part D could impact patients undergoing treatment for cancer.

Newsletter

Stay informed on drug updates, treatment guidelines, and pharmacy practice trends—subscribe to Pharmacy Times for weekly clinical insights.


Latest CME